R&D channel feed

#AAO22: In bid for first FDA nod in ge­o­graph­ic at­ro­phy, Apel­lis claims an­oth­er first in eye dis­ease field

3 years ago
Pharma

Up­dat­ed: Al­ny­lam re­in­forces APOL­LO-B patisir­an da­ta be­fore head­ing to the FDA

3 years ago
FDA+

Eu­ro­pean phar­ma group wants to cre­ate PRV-like sys­tem to spur an­tibi­otics R&D

3 years ago

In­ter­cep­t's OCA fails a PhI­II NASH tri­al, rais­ing fresh doubts about its years­long quest for an OK

3 years ago

Re­cent­ly out-of-stealth neu­ro­science out­fit un­veils cash raise, more de­tails on Lil­ly, North­west­ern pro­grams

3 years ago
Financing

As Amy­lyx de­ci­sion waits in the wings, Bio­haven’s ALS drug sinks (again) in plat­form tri­al

3 years ago

Ali­gos co-founders shoot back at J&J IP com­plaint with one of their own al­leg­ing fraud

3 years ago

Ax­cel­la touts in­ter­im NASH da­ta but needs cash to stay afloat for 2024 topline read­out

3 years ago

Wyss In­sti­tute spin­out looks to re­vamp drug de­vel­op­ment for CNS dis­eases — with CRISPR tad­poles

3 years ago
Startups

TCR²'s ga­vo-cel sur­vives a PhI test. Now it's head-first in­to PhII with a half-dozen par­tial re­spons­es

3 years ago

Bio­gen, Ei­sai re­fresh amy­loid hy­poth­e­sis with PhI­II show­ing Alzheimer's med slows cog­ni­tive de­cline

3 years ago

New Jer­sey biotech nets $50M+ BAR­DA con­tract for res­pi­ra­to­ry can­di­date

3 years ago
Pharma

Con­text Ther­a­peu­tics trims pipeline, cuts down on spend­ing to con­serve cash

3 years ago

Aque­s­tive touts PhII da­ta — and speed — in po­ten­tial EpiPen re­place­ment can­di­date

3 years ago

FDA slaps a par­tial hold on Avid­i­ty's mAb-siR­NA ther­a­py, paus­ing en­roll­ment in mus­cle weak­ness dis­ease study

3 years ago
FDA+

In sur­vival mode, Ex­i­cure cuts to the bone — paus­ing all R&D and chop­ping head­count by 66%

3 years ago
People

Even as pan­dem­ic re­cedes, short-staffed tri­al sites leave can­cer pa­tients wait­ing

3 years ago
Pharma
In Focus

Ar­cutis' for­mu­la­tion of old As­traZeneca drug clears an­oth­er PhI­II test

3 years ago

As­traZeneca, Mer­ck cull one Lyn­parza in­di­ca­tion in heav­i­ly pre­treat­ed ovar­i­an can­cer pa­tients

3 years ago

As­traZeneca shuts the PhI­II door for Ion­is' PC­SK9 drug de­spite pos­i­tive PhI­Ib

3 years ago

Up­dat­ed: Bio­gen throws it­self back in­to mud­dled da­ta ar­gu­ments with more de­tails on its an­ti­sense ALS drug

3 years ago

In­ven­ti­va signs over Chi­na NASH rights to Sino Bio­pharm in pos­si­ble $300M+ deal

3 years ago
Deals

CD­MO makes an AI and drug dis­cov­ery play in lat­est, small-time ac­qui­si­tion

3 years ago
Manufacturing

Mer­ck KGaA teams up with Ital­ian on­col­o­gy group in PARP1 de­vel­op­ment deal

3 years ago
Deals
First page Previous page 117118119120121122123 Next page Last page
A service from the Financial Times